Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 17 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Reduction Not Only in Recurrences, but Also in Mortality, Observed for... December 20, 2022 Reflections from the World Cancer Congress November 30, 2022 New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... December 7, 2020 Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... August 31, 2020 Load more HOT NEWS 11 top tips for cutting back on alcohol 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer News digest – ovarian cancer blood test, statins, spending review and...
